Title: Evolutionary algorithms and artificial intelligence in drug discovery: opportunities, tools, and prospects

Authors: Moolchand Sharma; Suman Deswal

Addresses: Maharaja Agrasen Institute of Technology, Rohini, Delhi, India ' Deenbandhu Chhotu Ram University of Science and Technology, Murthal (Sonipat), Haryana, India

Abstract: The drug design process is lengthy, complex, and dependent on several factors. Developing a medicine can take 10 to 15 years, from discovery to commercialisation. Machine learning (ML) refers to a set of tools that can assist you in learning more and making better decisions for well-defined questions with a large amount of data. The opportunities to use ML occur throughout the drug development process. Examples include target identification and validation, identification of alternative targets, and biomarker identification. Some approaches have produced accurate predictions and insights, while others have not. But to deal with high-dimensional data, we need soft-computing methods to find the best solution, which could be a new drug. This article provides a detailed overview of various ML, evolutionary algorithms, and soft computing techniques surveyed and analysed for de novo drug design, emphasising the computational aspects.

Keywords: drug design; machine learning; evolutionary algorithms; target identification; soft computing; artificial intelligence; deep neural networks; DNNs.

DOI: 10.1504/IJNVO.2022.130941

International Journal of Networking and Virtual Organisations, 2022 Vol.27 No.4, pp.267 - 297

Received: 14 Apr 2022
Accepted: 09 Nov 2022
Published online: 14 May 2023 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article